postpartum hemorrhage
Conditions
Interventions
Group A(vaginal delivery):ergometrine maleate + oxytocin injection
Group B(vaginal delivery):oxytocin injection
Group C(cesarean delivery):ergometrine maleate + oxytocin injection
Group D(cesarean delivery):oxytocin injection
Sponsors
West China Second University Hospital of Sichuan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) The subjects is voluntarily participated, and the informed consent form is signed in person or by the legal guardian; 2) Aged 20-40 years old; 3) Parturient woman with natural labor and cesarean delivery: gestational weeks were 37 weeks to 41 weeks + 6 days.
Exclusion criteria
Exclusion criteria: 1) Patients with severe medical complications (heart disease, liver disease, kidney disease, etc.); abnormal liver and kidney function; or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values is exceeding 2 times of the upper limit of normal value; or creatinine (Cr) is greater than the upper limit of normal; 2) Those with severe endocrine diseases (pre-pregnancy diabetes, hyperthyroidism, etc.); 3) Pregnancy-induced hypertension and sepsis; 4) genital malformations, uterine infections; 5) placenta implant or sinister placenta previa; 6) failure of trial production, transfer to cesarean section; 7) abdominal surgery= 2 times, delivery= 4 times; 8) hemoglobin 3, a single fibroid = 2cm; 11) subjects who are taking HIV protease inhibitors; 12) Those who are allergic to oxytocin or ergometrine maleate; 13) Those who have participated in other clinical research within the first three months of the selection; 14) The investigator believes that it is not suitable for the participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood loss; | — |
Countries
China
Contacts
Public ContactLiu Xinghui
West China Second University Hospital of Sichuan University
Outcome results
None listed